KSKatie Snape

Katie Snape

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katie Snape has a total of 302 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genomic Analysis Using Liquid Biopsy: Considerations for Pretest Counseling in UK Practice

    by David John McMahon, Elizabeth Bancroft, George J. Burghel, Ellen Copson, Michael Hubank, Jennifer Wiggins, Katie Snape, Natalie Cook, Ian Frayling, Matthew J. Murray, et al.

    Modern cancer diagnostics is heavily reliant on molecular data. Next-generation sequencing using liquid biopsy (LB) is primarily focused on identifying predictive and prognostic biomarkers to guide systemic therapy decision making. However, additional findings including genomic variants of possible or probable germline origin are detected in a significant minority of patients (3%-18%), with significant implications for patients and their families. Pretest information provision regarding both the purpose and potential benefits of the test and additional findings on LB varies in clinical practice, with little guidance for clinicians regarding the degree of detail required regarding possible additional findings. LB requires explicit disclosure of these aspects. Implementing a standardized, context-dependent approach to this discussion, with nationally standardized information provision tools, should be prioritized to enable patient-centered decision making regarding LB, without prioritizing the incidentalome over the primary purpose of the test—refining and optimizing treatment options.

  • Open Access

    Identification and management of genetic susceptibility to cancer: UK perspective

    by Ciaran McCarthy, Katie Snape

    Cancer is a genomic disease caused by variants in genes that impact on the regulation of cell division, cell growth and cell death. While the majority of cancers are caused by acquired genomic variation, a significant minority are influenced by inherited genetic variation which can increase the chance of a person developing cancer in their lifetime. Inherited genetic factors can be monogenic or polygenic and also interact with other cancer risk factors to create an individualised risk profile. Understanding personalised cancer risk can facilitate precision screening, prevention and early detection strategies. In this review, we give an overview of constitutional genetic susceptibility to cancer, how to assess and identify enhanced susceptibility and exemplars of how this influences precision management.


  • Open Access

    Clinical validation of large-scale functional assays: insights from 2,120 gene-truthset-assay evaluations

    by Sophie Allen, Charlie F. Rowlands, Zeid Kuzbari, Alice Garrett, Miranda Durkie, George J. Burghel, Rachel Robinson, Alison Callaway, Joanne Field, Bethan Frugtniet, et al.

    Background: Clear guidance is lacking regarding how ‘truthset’ variants should be used for clinical validation of functional assays, namely determining the allocatable evidence points (EPs) towards clinical classification. It is argued that assays should be validated using truthsets of missense variants, as this is the variant type for which classification is most impacted by functional data. EPs will be influenced by both the number of available ‘truthset’ variants and their concordance with assay readouts. Methods: We first reviewed 112 sets of ClinGen gene-specific classification specifications (CSPECs) to assess methodologies they applied for truthset assembly and clinical validation of assays. We then proposed differing rules regarding variant type and stringency of classification by which truthsets might be assembled using ClinVar-extracted classifications. We then examined augmentation of ClinVar-classified truthsets with ‘proxy-clinical’ benign-classified missense variants systematically assembled applying ACMG/AMP rules (of differing stringencies). In total, these constituted 70 basic approaches to ClinVar-based truthset assembly, which we applied to VHL, BRCA1, BRCA2 and RAD51C . We additionally analysed the impact on the size of the truthsets of changing the specified phenotypes against which ClinVar classification had been submitted. We then applied these truthsets to quantify concordance and allocatable EPs for five large-scale multiplexed functional assays for VHL , BRCA1 , BRCA2 , and RAD51C . Results: The EPs from clinical validation of each assay varied widely according to which truthset was used across 2,120 permutations of gene-truthset-assay combinations. For example, sequentially applying 700 different ClinVar-based truthsets to 2,268 VHL assay variant readouts (70 basic ClinVar-based approaches, augmented by examining 5 different phenotypes for each basic approach, and separate validation against two defined deleterious zones), the evidence strength allocatable for pathogenicity ranged from nil to strong evidence (0.0 to 5.6 EPs); for benignity it ranged from supporting to strong evidence (-1.5 to -6.4 EPs). Clinical validation using truthsets comprising just ClinVar-classified missense variants typically resulted in lower EPs than truthsets comprising protein truncating (PTV) and synonymous variants; this was more due to paucity of ClinVar-classified missense truthset variants than poorer concordance. Augmentation with larger ‘proxy-clinical’ benign-classified missense truthsets typically improved evidence allocatable for pathogenicity, with improved power negating modest reduction in concordance. Conclusions: EPs can be improved by augmentation with systematically-generated ‘proxy-clinical’ benign-classified missense variants and/or reduction of truthset stringency. Explicit prescriptive clinical guidance is urgently required to improve consistency in clinical validation of functional assays and consequent evidence application for clinical variant classification.


  • Open Access

    ‘Truthsets’ for clinical validation of large-scale functional assays: Practice recommendations from Cancer Variant Interpretation Group UK (CanVIG-UK)

    by Sophie Allen, Charlie F. Rowlands, Alice Garrett, Zeid Kuzbari, Miranda Durkie, George J. Burghel, Rachel Robinson, Alison Callaway, Joanne Field, Bethan Frugtniet, et al.

    Background: Large-scale functional assays, including multiplex assays of variant effect, have substantial potential to resolve variants of uncertain significance (VUS), particularly for rare missense variants where clinical and population evidence are limited. The ClinGen assay-level clinical validation framework described by Brnich et al provided baseline guidance for the use of functional data for variant classification. However, clear consensus regarding construction of variant ‘truthsets’ by which to clinically validate functional data remains lacking. Methods: CanVIG-UK developed consensus recommendations for truthset construction through an iterative national consultation process involving the CanVIG Steering Advisory Group (CStAG), wider CanVIG-UK membership, and engagement with international functional genomics experts. Consultation was based on previous analyses of 2,120 truthset constructions examining the impact of truthset composition on evidence point allocation within the ClinGen assay-level clinical validation framework. Results: Across several consultations, CanVIG-UK established nine guiding principles and seven best-practice recommendations for assay-level clinical validation, using the assumed context of an assay for a cancer susceptibility gene where loss-of-function is the mechanism of pathogenicity. The principal recommendation stipulates, where assays are intended for use in interpretation of largely missense variants, the truthset used to validate should comprise only missense variants. Rather than mixtures of different variant types which may serve to over-estimate assay performance. Additional recommendations support option for relaxation of truthset stringency to improve power, augmentation of benign missense truthsets with systematically derived ‘proxy-clinical’ benign variants, independent clinical validation separate from assayist-defined validation, and careful evaluation of missense score distributions against that of protein-truncating and synonymous variants. Guidance is also provided for scenarios with limited pathogenic truthset availability and for assays reporting multiple deleterious zones or readouts. Conclusions: The CanVIG-UK principles and recommendations for truthset construction upon the ClinGen assay-level clinical validation framework, while aiming to form a baseline for future discussion regarding other functional and disease contexts and helping to address the gap between publication of new data and routine clinical implementation.

  • Open Access

    CanVar-UK: an online data platform supporting collaborative diagnostic interpretation of germline variants in cancer susceptibility genes

    by Charlie F. Rowlands, Subin Choi, Sophie Allen, Zeid Kuzbari, Cankut Çubuk, Razvan Sultana, Beth Torr, Miranda Durkie, George J. Burghel, Rachel Robinson, et al.

    Interpretation of germline variants in cancer susceptibility genes (CSGs) requires the collation of variant-level data from diverse sources, as well as the assembly of comprehensive clinical data, often necessitating sharing of information between genomic testing centers. Although a number of variant interpretation tools exist, there remains a need for a CSG-focused platform tailored to the diverse range of ClinGen variant curation expert panel guidance in these difficult-to-interpret genes. Here, we describe CanVar-UK, a freely-accessible web platform to assist in the interpretation of germline CSG variants. CanVar-UK contains variant-level data for over 1.7 million single nucleotide variants, comprising all coding variants in 115 established CSGs. These data include: in silico scores from 11 tools of clinical relevance; population allele frequencies from gnomAD v4.1 and case counts from NHS genomic testing via linkage to the National Disease Registration Service; variant-level readouts from 31 different functional and splicing studies across 13 CSGs; genetic epidemiology studies of the BRCA1/2 genes; and live linkage to existing consensus classifications in the ClinVar database. CanVar-UK additionally has a diagnostic discussion forum functionality, via which users are able to email the rest of the user base with queries and/or suggested classifications, facilitating the exchange of clinical and classification data between diagnostic centers. Already widely used by the NHS clinical workforce in the CSG space (with 879 registered NHS users), CanVar-UK has a rapidly growing international user base, with 607 registered users based outside the UK. We believe CanVar-UK to be an invaluable resource for germline CSG variant interpretation.


  • Predicting the differential diagnosis of inherited versus acquired bone marrow failure syndromes: Development of simple clinical scoring systems

    by Marta Bortolotti, Bruno Fattizzo, Simona Stella, Jie Jiang, Francesco Versino, Clair Engelbrecht, Roochi Trikha, Joanna Large, Shreyans Gandhi, Katie Snape, et al.


  • Open Access

    Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC and renal cancer

    by Sophie Allen, Charlie F Rowlands, Samantha Butler, Miranda Durkie, Carrie Horton, Tina Pesaran, Marcy Richardson, Rachel Robinson, Alice Garrett, George J Burghel, et al.


  • Open Access

    Availability of benign missense variant “truthsets” for validation of functional assays: current status and a novel systematic approach

    by Charlie F. Rowlands, Sophie Allen, Alice Garrett, Miranda Durkie, George J. Burghel, Rachel Robinson, Alison Callaway, Joanne Field, Bethan Frugtniet, Sheila Palmer-Smith, et al.

    Multiplex assays of variant effect (MAVEs) provide promising new sources of functional evidence, potentially empowering improved classification of germline genomic variants, particularly rare missense variants, which are commonly assigned as VUS (variants of uncertain significance). However, paradoxically, quantification of clinically applicable evidence strengths for MAVEs requires construction of “truthsets” comprising missense variants already robustly classified as pathogenic and benign. In this study, we demonstrate how benign truthset size is the primary driver of applicable functional evidence towards pathogenicity (PS3). We demonstrate, when using existing ClinVar classifications as a source of benign missense truthset variants, for only 19.8% (23/116) of established cancer susceptibility genes was a PS3 evidence strength of “strong” attainable when simulating validation for a hypothetical new MAVE (applying also favourable assumption of perfect concordance). We describe a “proactive-systematic” framework for benign truthset construction, in which all possible missense variants in a gene of interest are concurrently assessed for assignation of (likely) benignity via established ACMG/AMP combination rules including population frequency, in silico evidence codes and case-control signal. We apply this framework to eight hereditary breast and ovarian cancer genes, demonstrating that proactive-systematically generated benign missense truthsets allow maximum application of PS3 at greater (or equivalent) strength – reaching “moderate” for CHEK2 and “strong” for the other seven genes – than those derived from ClinVar ≥2* classifications alone. We propose, given many genes have few existing benign-classified missense variants, application of this proactive-systematic framework to disease genes more broadly will be important for leveraging full value from MAVEs.


  • Open Access

    Impact of NICE Guideline NG241 ‘Ovarian Cancer: identifying and managing familial and genetic risk’ on a regional NHS family history and clinical genetics service

    by Alexander Roe, Andrea Forman, Fiona Lalloo, Terri P McVeigh, Helen Hanson, Katie Snape

    Background NICE Guideline NG241: identifying and managing familial and genetic risk of ovarian cancer (OC) was published by the National Institute for Health and Care Excellence (NICE) in March 2024. NG241 advises germline genetic testing of genes predisposing to OC in unaffected individuals with an OC family history at different mutation likelihood thresholds depending on age and sex, ranging from 2% to 10% likelihood of finding a germline pathogenic variant (GPV). Prior to implementation of NG241, updates to the NHS England National Genomic Test Directory would be required. Clinical genetics services have to consider equity of access to assessment and testing across all familial cancer types, best use of their limited resources and other factors such as complexity of delivery of clinical pathways. Methods We analysed data from 8011 patients who provided digital family histories to the South West Thames Centre for Genomics between October 2019 and June 2024. Results We estimate 527/782 (68%) females and 28/77 (36%) males would meet test criteria for NICE NG241. We estimate we would reject 2919/5485 (53%) females and 135/1208 (11%) males with the same likelihood of carrying a GPV, but with a breast cancer rather than OC family history. Testing the familial OC cohort at a universal 5% threshold in OC families would detect ~11 carriers for 229 tests compared with ~8 carriers for 278 tests following NG241 criteria. Conclusion Our data highlight additional factors needing to be considered before the NICE Guideline NG241 can be implemented by regional genetics services.


  • Open Access

    THE BIOLOGICAL SECTION (23 AUGUST 2024) WITHIN THE XXIV GAMOW INTERNATIONAL ASTRONOMICAL CONFERENCE “ASTRONOMY AND BEYOND: ASTROPHYSICS, COSMOLOGY AND GRAVITATION, ASTROPARTICLE PHYSICS, RADIO ASTRONOMY, ASTROBIOLOGY AND GENETICS”, HELD ON 19–23 AUGUST 2024 AT ODESA I. I. MECHNIKOV NATIONAL UNIVERSITY, ODESA CITY, UKRAINE

    by M. Borisjuk, A. Stepanenko, G. Chen, T. Michael, E. Lem, V. Schubert, I. Schubert, Yu. O. Tynkevich, I. I. Panchuk, R. A. Volkov, et al.

    It was the sixth session of the Biological Section within the Gamow International Astronomical Conference that took place on 23 August 2024. The Biological Section was traditionally held under the title “Importance of G. Gamov’s Ideas for the Biology of the 21st Century.” This year, 39 scientists and students participated in the work of the section. Scientists from Ukraine, Germany, Great Britain, Denmark, Canada and the USA presented their scientific reports. Those reports covered research based on the studies of nucleotide sequences of genes and genomes of various biological species.